Piper Sandler Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $15
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $21 to $15.
Piper Sandler analyst Biren Amin maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $21 to $15.